{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:04:40Z","timestamp":1793945080432,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PM_217648"],"award-info":[{"award-number":["P500PM_217648"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lungcan.2024.107963","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:40:22Z","timestamp":1727674822000},"page":"107963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["MTAP as an emerging biomarker in thoracic malignancies"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-1377","authenticated-orcid":false,"given":"Magdalena M.","family":"Brune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spasenija","family":"Savic Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Vlajnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-5947","authenticated-orcid":false,"given":"Obinna","family":"Chijioke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-5372","authenticated-orcid":false,"given":"Luca","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6855","authenticated-orcid":false,"given":"David","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5970-1803","authenticated-orcid":false,"given":"Lukas","family":"Bubendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.lungcan.2024.107963_b0010","unstructured":"Sauter JL. WHO Classification of Tumours Editorial Board. Thoracic tumours [Internet]. Lyon: Lyon (France): International Agency for Research on Cancer."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0015","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.21037\/tlcr-20-676","article-title":"Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas","volume":"9","author":"Matter","year":"2020","journal-title":"Transl Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"22","key":"10.1016\/j.lungcan.2024.107963_b0030","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.lungcan.2024.107963_b0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.lungcan.2024.107963_b0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol off J Am Soc Clin Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107963_b0055","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.3390\/cancers15102733","article-title":"Factors predictive of primary resistance to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"15","author":"Huang","year":"2023","journal-title":"Cancers."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107963_b0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."},{"key":"10.1016\/j.lungcan.2024.107963_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264785","article-title":"The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality","volume":"13","author":"Bray","year":"2023","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0070","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107963_b0075","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/iub.278","article-title":"Metabolic characteristics and importance of the universal methionine salvage pathway recycling methionine from 5\u2019-methylthioadenosine","volume":"61","author":"Albers","year":"2009","journal-title":"IUBMB Life."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107963_b0080","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/13543776.2022.2119127","article-title":"A patent review of MAT2a inhibitors (2018\u20132021)","volume":"32","author":"Atkinson","year":"2022","journal-title":"Expert Opin Ther Pat."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol Cancer Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107963_b0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0095","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/genes14030678","article-title":"The Role of PRMT5 in Immuno-Oncology","volume":"14","author":"Abe","year":"2023","journal-title":"Genes."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13402-020-00577-7","article-title":"Protein arginine methyltransferase 5: a potential cancer therapeutic target","volume":"44","author":"Yuan","year":"2021","journal-title":"Cell Oncol."},{"issue":"6278","key":"10.1016\/j.lungcan.2024.107963_b0105","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.lungcan.2024.107963_b0110","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ajpath.2010.11.059","article-title":"Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5\u2019-deoxy-5\u2019-methylthioadenosine (MTA)","volume":"178","author":"Kirovski","year":"2011","journal-title":"Am J Pathol."},{"issue":"49","key":"10.1016\/j.lungcan.2024.107963_b0120","doi-asserted-by":"crossref","first-page":"e2271","DOI":"10.1097\/MD.0000000000002271","article-title":"Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma","volume":"94","author":"He","year":"2015","journal-title":"Medicine (baltimore)."},{"key":"10.1016\/j.lungcan.2024.107963_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-019-0035-z","article-title":"Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma","volume":"4","author":"Xu","year":"2019","journal-title":"Signal Transduct Target Ther."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107963_b0130","first-page":"1143","article-title":"MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients","volume":"40","author":"Su","year":"2014","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0135","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza","year":"2023","journal-title":"Am J Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107963_b0140","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1073\/pnas.0408593102","article-title":"A survey of homozygous deletions in human cancer genomes","volume":"102","author":"Cox","year":"2005","journal-title":"Proc Natl Acad Sci U S a."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107963_b0145","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/2159-8290.CD-23-0951","article-title":"Early clinical success of MTA-cooperative PRMT5 inhibitors for the treatment of CDKN2A\/MTAP-deleted cancers","volume":"13","author":"Mulvaney","year":"2023","journal-title":"Cancer Discov."},{"issue":"7283","key":"10.1016\/j.lungcan.2024.107963_b0150","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0155","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2024.107963_b0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107963_b0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/cncy.21429","article-title":"Targeted multiprobe fluorescence in situ hybridization analysis for elucidation of inconclusive pancreatobiliary cytology","volume":"122","author":"Vlajnic","year":"2014","journal-title":"Cancer Cytopathol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0170","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107963_b0175","doi-asserted-by":"crossref","unstructured":"Vlajnic T, Chijioke O, Roma L, Savic Prince S, Zellweger T, Rentsch CA, et al. Loss of MTAP expression by immunohistochemistry is a surrogate marker for homozygous 9p21.3 deletion in urothelial carcinoma. Mod Pathol Off J U S Can Acad Pathol Inc. 2024 Apr 17;100495.","DOI":"10.1016\/j.modpat.2024.100495"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107963_b0180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/bjc.2017.209","article-title":"Clinical study of genomic drivers in pancreatic ductal adenocarcinoma","volume":"117","author":"Barrett","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/cbt.4.1.1380","article-title":"Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy","volume":"4","author":"Hustinx","year":"2005","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.lungcan.2024.107963_b0190","doi-asserted-by":"crossref","unstructured":"Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod Pathol Off J U S Can Acad Pathol Inc. 2022;35(10):1383\u201397.","DOI":"10.1038\/s41379-022-01081-z"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ajcp\/aqab091","article-title":"Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma","volume":"157","author":"Terra","year":"2022","journal-title":"Am J Clin Pathol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107963_b0200","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.lungcan.2024.107963_b0205","doi-asserted-by":"crossref","unstructured":"Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol Off J U S Can Acad Pathol Inc. 2020;33(2):245\u201354.","DOI":"10.1038\/s41379-019-0310-0"},{"key":"10.1016\/j.lungcan.2024.107963_b0210","doi-asserted-by":"crossref","unstructured":"Febres-Aldana CA, Chang JC, Jungbluth AA, Adusumilli PS, Bodd FM, Frosina D, et al. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma. Mod Pathol Off J U S Can Acad Pathol Inc. 2024;37(3):100420.","DOI":"10.1016\/j.modpat.2023.100420"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cncy.22777","article-title":"The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens","volume":"132","author":"Yu","year":"2024","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.lungcan.2024.107963_b0220","unstructured":"Gorbokon N, W\u00f6\u00dfner N, Lennartz M, Dwertmann Rico S, Kind S, Reiswich V, et al. Prevalence of MTAP deficiency in human cancer: A tissue microarray study on 17,078 tumors from 149 different tumor types. Am J Surg Pathol in press."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0225","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","article-title":"Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy","volume":"6","author":"Ebot","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107963_b0235","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107963_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.13587","article-title":"MTAP deficiency contributes to immune landscape remodelling and tumour evasion","volume":"168","author":"Chang","year":"2023","journal-title":"Immunology"},{"issue":"14","key":"10.1016\/j.lungcan.2024.107963_b0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.18632\/oncotarget.28376","article-title":"Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss","volume":"11","author":"Bou Zerdan","year":"2023","journal-title":"Oncotarget."},{"issue":"14","key":"10.1016\/j.lungcan.2024.107963_b0255","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","article-title":"Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance","volume":"24","author":"Ye","year":"2018","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107963_b0260","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neo.2021.08.004","article-title":"Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy","volume":"23","author":"Razaghi","year":"2021","journal-title":"Neoplasia N Y n."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107963_b0265","first-page":"1367","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat","volume":"3","author":"Barriga","year":"2022","journal-title":"Cancer."},{"issue":"15","key":"10.1016\/j.lungcan.2024.107963_b0270","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1093\/nar\/gkp516","article-title":"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function","volume":"37","author":"Scoumanne","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107963_b0275","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107963_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0285","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107963_b0290","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J Med Chem."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0295","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5\u2022MTA Complex for the Treatment of MTAP-Deleted Cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem."},{"key":"10.1016\/j.lungcan.2024.107963_b0300","doi-asserted-by":"crossref","unstructured":"Rodon J, Yamamoto N, Doi T, Ghiringhelli F, Goebeler ME, Fujuwara Y, et al. Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors [abstract].Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr PR006.","DOI":"10.1158\/1535-7163.TARG-23-PR006"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0305","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (prmt5) inhibitors in oncology clinical trials: a review","volume":"5","author":"Feustel","year":"2022","journal-title":"J Immunother Precis Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0310","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0315","doi-asserted-by":"crossref","first-page":"G184","DOI":"10.1152\/ajpgi.2001.280.2.G184","article-title":"Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer","volume":"280","author":"Yang","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.gastro.2007.03.114","article-title":"Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells","volume":"133","author":"Chen","year":"2007","journal-title":"Gastroenterology."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell."},{"issue":"716","key":"10.1016\/j.lungcan.2024.107963_b0330","article-title":"The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity","volume":"27","author":"Xuan","year":"2024","journal-title":"Biochem Biophys Res Commun."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107963_b0335","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/CCO.0000000000000870","article-title":"Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy","volume":"34","author":"Guo","year":"2022","journal-title":"Curr Opin Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107963_b0340","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0022-5347(05)64270-X","article-title":"Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer","volume":"168","author":"Sarosdy","year":"2002","journal-title":"J Urol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0345","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cncr.10881","article-title":"DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine","volume":"96","author":"Dalquen","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000323652","article-title":"Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma - FISHing for the right catch","volume":"55","author":"Bubendorf","year":"2011","journal-title":"Acta Cytol."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107963_b0355","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/j.1572-0241.2004.30281.x","article-title":"A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures","volume":"99","author":"Kipp","year":"2004","journal-title":"Am J Gastroenterol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107963_b0360","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jgh.12575","article-title":"Endoscopic ultrasound guided fine needle aspiration with fluorescence in situ hybridization analysis in 104 patients with pancreatic mass","volume":"29","author":"Ribeiro","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.10923","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei","year":"2003","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0370","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3892\/ol.2021.13074","article-title":"Short 57 kb CDKN2A FISH probe effectively detects short homozygous deletion of the 9p21 locus in malignant pleural mesothelioma","volume":"22","author":"Oyama","year":"2021","journal-title":"Oncol Lett."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107963_b0375","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.0.CO;2-Q","article-title":"Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization","volume":"74","author":"Okami","year":"1997","journal-title":"Int J Cancer."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107963_b0380","first-page":"687","article-title":"Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers","volume":"1","author":"Packenham","year":"1995","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"10 Suppl","key":"10.1016\/j.lungcan.2024.107963_b0385","first-page":"2410","article-title":"Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers","volume":"53","author":"Olopade","year":"1993","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00439-019-02093-7","article-title":"Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression","volume":"139","author":"Tremmel","year":"2020","journal-title":"Hum Genet."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0395","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41467-018-03273-1","article-title":"Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes","volume":"9","author":"Numanagi\u0107","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.lungcan.2024.107963_b0400","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.796249","article-title":"KNNCNV: A K-Nearest Neighbor Based Method for Detection of Copy Number Variations Using NGS Data","volume":"9","author":"Xie","year":"2021","journal-title":"Front Cell Dev Biol."},{"issue":"20","key":"10.1016\/j.lungcan.2024.107963_b0405","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.3390\/cancers15204978","article-title":"Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma","volume":"15","author":"Vrugt","year":"2023","journal-title":"Cancers."},{"key":"10.1016\/j.lungcan.2024.107963_b0410","doi-asserted-by":"crossref","unstructured":"Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, et al. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Mod Pathol Off J U S Can Acad Pathol Inc. 2020 Feb;33(2):217\u201327.","DOI":"10.1038\/s41379-019-0371-0"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107963_b0415","first-page":"466","article-title":"Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A\/B homozygous deletion in gliomas","volume":"55","author":"Maragkou","year":"2023","journal-title":"Pathology (phila)."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107963_b0420","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.14324","article-title":"Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma","volume":"78","author":"Chapel","year":"2021","journal-title":"Histopathology."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107963_b0425","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0002-9440(10)63695-4","article-title":"Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma","volume":"163","author":"Behrmann","year":"2003","journal-title":"Am J Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107963_b0430","first-page":"985","article-title":"Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency","volume":"26","author":"Ishii","year":"2005","journal-title":"Int J Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107963_b0435","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbadis.2004.08.002","article-title":"Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma","volume":"1690","author":"Berasain","year":"2004","journal-title":"Biochim Biophys Acta BBA - Mol Basis Dis."},{"key":"10.1016\/j.lungcan.2024.107963_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2022.152004","article-title":"Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma\/sarcomatoid pleural mesothelioma with desmoplastic features","volume":"60","author":"Sa-Ngiamwibool","year":"2022","journal-title":"Ann Diagn Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2008.04.019","article-title":"Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma","volume":"63","author":"Watanabe","year":"2009","journal-title":"Lung Cancer Amst Neth."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107963_b0450","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-020-57812-2","article-title":"MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab","volume":"10","author":"Jing","year":"2020","journal-title":"Sci Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:05:39Z","timestamp":1731999939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":90,"alternative-id":["S0169500224004975"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107963","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MTAP as an emerging biomarker in thoracic malignancies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107963"}}